What's new — Asthma¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 5 |
| last 2 months | 8 |
| last 3 months | 9 |
| last 6 months | 13 |
| last year | 19 |
| older than a year | 395 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-04 | High-dose vitamin D(3) supplementation in the prevention of viral-induced asthma in high-morbidity preschoolers (DIVA): a randomised controlled trial in Canada — EClinicalMedicine ([PMID 42871976](https://pubmed.ncbi.nlm.nih.gov/42871976/){target="_blank" rel="noopener"}) | asthma-in-children |
| 2026-10-02 | Comorbidity Burden and Clinical Management Challenges in Severe Asthma: Insights from a Pan-European SHARP Study — J Asthma Allergy ([PMID 42936732](https://pubmed.ncbi.nlm.nih.gov/42936732/){target="_blank" rel="noopener"}) | comorbidity-and-mimics |
| 2026-10-02 | Impact of air pollution exposure in early life on lung function development in the COPSAC cohorts — BMJ Open Respir Res ([PMID 42933820](https://pubmed.ncbi.nlm.nih.gov/42933820/){target="_blank" rel="noopener"}) | genetics-environment-and-prevention |
| 2026-10-02 | The Effect of Nasal Corticosteroids and Antihistamines on Asthma Control in Patients with Asthma and Comorbid Allergic Rhinitis: A Systematic Review — J Asthma ([PMID 42904911](https://pubmed.ncbi.nlm.nih.gov/42904911/){target="_blank" rel="noopener"}) | comorbidity-and-mimics |
| 2026-10-02 | A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE study — Eur Respir J ([PMID 42242757](https://pubmed.ncbi.nlm.nih.gov/42242757/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-09-01 | Application of type 2 inflammation-related biomarkers in risk prediction models for acute exacerbations in adult asthma: a systematic review — Front Med (Lausanne) ([PMID 42827866](https://pubmed.ncbi.nlm.nih.gov/42827866/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-09-01 | Prevalence of asthma among African children and adolescents: findings from the Chronic Respiratory Disease Observatory for Africa (CHEST-Africa) — Thorax ([PMID 42744587](https://pubmed.ncbi.nlm.nih.gov/42744587/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden |
| 2026-09-01 | Accuracy of type 2 inflammatory biomarkers to diagnose asthma in adults and children: a meta-analysis of 30 studies with prospective validation in an adult primary care cohort — Lancet Respir Med ([PMID 42743935](https://pubmed.ncbi.nlm.nih.gov/42743935/){target="_blank" rel="noopener"}) | biomarkers, diagnosis-and-objective-testing |
| 2026-08-02 | Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies — Lancet Respir Med ([PMID 42624803](https://pubmed.ncbi.nlm.nih.gov/42624803/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-07-07 | Smart Inhaler Randomized Controlled Trial for Improving Inhaler Technique in Adolescents With Intellectual and Developmental Disabilities and Asthma — Acad Pediatr ([PMID 42413691](https://pubmed.ncbi.nlm.nih.gov/42413691/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-07-02 | Global economic burden attributable to asthma, 2025-50: a global modelling analysis of 154 countries and territories — Lancet Respir Med ([PMID 42520825](https://pubmed.ncbi.nlm.nih.gov/42520825/){target="_blank" rel="noopener"}) | epidemiology-and-global-burden |
| 2026-07-02 | Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial — Adv Ther ([PMID 42474701](https://pubmed.ncbi.nlm.nih.gov/42474701/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-07-01 | Defining Minimal Clinical Disease Activity and Remission in Severe Asthma: A Modified Delphi Consensus — J Allergy Clin Immunol Pract ([PMID 42463041](https://pubmed.ncbi.nlm.nih.gov/42463041/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-05-02 | Depemokimab reduces asthma exacerbations similarly to other biologics — Ann Allergy Asthma Immunol ([PMID 42173441](https://pubmed.ncbi.nlm.nih.gov/42173441/){target="_blank" rel="noopener"}) | severe-asthma-and-biologics |
| 2026-05-02 | Glucagon-Like Peptide-1 Receptor Agonists in Asthma and Obesity-Associated Asthma: A Systematic Review of Clinical Outcomes and Translational Mechanisms — J Allergy Clin Immunol Pract ([PMID 42167405](https://pubmed.ncbi.nlm.nih.gov/42167405/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-05-01 | Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE) — Am J Respir Crit Care Med ([PMID 41738176](https://pubmed.ncbi.nlm.nih.gov/41738176/){target="_blank" rel="noopener"}) | severe-asthma-and-biologics |
| 2026-04-02 | Meta-Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force — Allergy ([PMID 42011838](https://pubmed.ncbi.nlm.nih.gov/42011838/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-02-05 | Macrolides for asthma: A systematic review and meta-analysis of randomized trials — J Allergy Clin Immunol ([PMID 41654262](https://pubmed.ncbi.nlm.nih.gov/41654262/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2025-12-01 | Decreasing inhaled corticosteroids in pregnancy increases the risk for asthma exacerbations: time for new approaches to solve a decades-old problem — Eur Respir J ([PMID 41412710](https://pubmed.ncbi.nlm.nih.gov/41412710/){target="_blank" rel="noopener"}) | pregnancy-and-reproductive-health |
Trials — what has moved¶
23 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 5 |
| trial records updated in the last 2 months | 8 |
| trial records updated in the last 3 months | 10 |
| trial records updated in the last 6 months | 17 |
| trial records updated in the last year | 18 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non- | PHASE4 | 1358 | Change From Baseline (CFB) in Trough Forced Expiratory Volume in 1 Sec | 17 | 22 | 1 |
| 2026-05-18 | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benra | PHASE3 | 1717 | Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks | 157 | 1141 | 1 |
18 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| asthma-in-children | 2026-10-04 | 1 | 27 |
| clinical-trials-landscape | 2026-10-02 | 6 | 22 |
| comorbidity-and-mimics | 2026-10-02 | 2 | 28 |
| genetics-environment-and-prevention | 2026-10-02 | 1 | 30 |
| biomarkers | 2026-09-01 | 3 | 29 |
| diagnosis-and-objective-testing | 2026-09-01 | 1 | 27 |
| epidemiology-and-global-burden | 2026-09-01 | 2 | 28 |
| severe-asthma-and-biologics | 2026-05-02 | 2 | 30 |
| red-flags-and-safety-concerns | 2026-04-02 | 1 | 28 |
| pregnancy-and-reproductive-health | 2025-12-01 | 1 | 27 |
| guidelines | 2025-09-02 | 0 | 26 |
| patient-experience-and-advocacy | 2025-08-01 | 0 | 30 |
| exacerbations-and-acute-care | 2025-07-01 | 0 | 28 |
| mild-and-moderate-asthma | 2025-05-01 | 0 | 26 |
| overview | 2025-04-08 | 0 | 26 |
| phenotypes-endotypes-and-treatable-traits | 2025-04-08 | 0 | 28 |
| inhaler-technique-adherence-and-self-management | 2025-03-01 | 0 | 29 |
| airway-immunobiology-and-remodeling | 2023-08-01 | 0 | 32 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.